

IQVIA Disease Analyzer Germany

First published: 01/02/2024

Last updated: 18/08/2025

Data source

Human

Primary care medical records

Administrative details

Administrative details

Data source ID

104282

Data source acronym

IQVIA DA Germany

Data holder

[IQVIA](#)

Data source type

Primary care medical records

Main financial support

Funding by own institution

Funding from industry or contract research

Care setting

Primary care – GP, community pharmacist level

Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

Data source website

<https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights>

Contact details

Mui Van Zandt mui.vanzandt@iqvia.com

Main

mui.vanzandt@iqvia.com

Karel Kostev karel.kostev@iqvia.com

Alternate

karel.kostev@iqvia.com

Data source regions and languages

Data source countries

Germany

Data source languages

German

Data source establishment

Data source established

01/01/1992

Data source time span

First collection: 01/01/1992

The date when data started to be collected or extracted.

Publications

Data source publications

[Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic. AMA Psychiatry. 2023 Mar 1](#)

[Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID -19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiology and Drug Safety \(2022\)](#)

[Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ 2022](#)

[Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clin Epidemiol. 2022](#)

[DARWIN EU® - Prevalence of rare blood cancers in Europe](#)

Studies

List of studies that have been conducted using the data source

Prescribing of zolpidem in the primary care setting in France, Germany and the UK during 2012. (Prescribing of zolpidem in IMS Germany/France/UK)

A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Non-steroidal Anti-inflammatory Therapies in a Cohort of Patients with Ankylosing Spondylitis (AS) in the UK, France and Germany (MK-0663-163)

Drug utilisation study (DUS) on flupirtine-containing products Retrospective drug utilisation study using patient-level databases to characterise prescribing practices of flupirtine-containing drugs during routine clinical use and assess the main reasons for prescription by representative groups of prescribers

Indications for systemic fluoroquinolone prescribing in Europe: a descriptive population based study

Tramadol prescribing: a drug utilisation study using electronic data from France, Germany and the UK

A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases

Use of ondansetron in pregnant female patients in the IMS Disease Analyzer databases in France and Germany (Ondansetron use pregnancy)

Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)

Post-authorisation Safety Study to Evaluate the Long-term Safety of Dexamfetamine (Amfexa) (PASS for dexamfetamine)

Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)

Trends in prescriptions of valproate and valpromide for bipolar disorder in IMS France and IMS Germany between 2010 and June 2016 and in UK THIN between 1999 and 2015

Prevalence of hypereosinophilic syndrome (HES) in the paediatric population in EU (Hypereosinophilic syndrome in children)

DARWIN EU® Characterization of patients with chronic hepatitis B and C

Glucocorticoid-induced osteoporosis (GIOP): prescription patterns of glucocorticoids in paediatric patients

Prevalence of narcolepsy in two European countries - France and Germany

Incidence rates of morphea, systemic sclerosis and scleroderma

Incidence rates of Cutaneous T-Cell Lymphomas (CTCL) among patients with atopic dermatitis (AD)

Background incidence rates of Interstitial Lung Disease

DARWIN EU® DUS of Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use

Population incidence rates of pemphigoid in six European countries

Immune thrombocytopenia following vaccination with DTaP-IPV or TdaP-IPV in children

Prevalence of palmoplantar psoriasis and pustular psoriasis in children

Drug utilisation study of macrolide-containing medicinal products during pregnancy

Treatment patterns in patients with pulmonary arterial hypertension

Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers

Prevalence of multiple myeloma

Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection

Prevalence of Acute Liver Injury

DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022

DARWIN EU® Use of take-home naloxone for opioid overdose treatment

DARWIN EU® Drug utilization study of prescription opioids

DARWIN EU® - Co-prescribing of endothelin receptor antagonists (ERAs) and phosphodiesterate-5 inhibitors (PDE-5is) in pulmonary arterial hypertension (PAH)

DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus

Incidence of phimosis and paraphimosis in patients treated with SGLT2 inhibitors

DARWIN EU® EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant

DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis

DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations

DARWIN EU® Rates of occurrence of treatment-related intercurrent events in patients with major depressive disorder

DARWIN EU® Age specific incidence rates of RSV related disease in Europe

DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages

DARWIN EU® - Frailty and polypharmacy among adults with selected cancers at the time of diagnosis

Association between use of direct oral anticoagulants (DOACs) and increased risk of interstitial lung disease

DARWIN EU® - Drug utilisation study on medicinal use of Pelargonii radix

DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists

DARWIN EU® - Drug utilisation study on medicinal use of cannabis flos

DARWIN EU® - CGRP antagonists - Treatment patterns and users characteristics

Association between exposure to esomeprazole/omeprazole and risk of sexual dysfunction in men

DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe

DARWIN EU® - Azathioprine - user characteristics

DARWIN EU® – Paracetamol prescribing and paracetamol overdose in Europe: a descriptive analysis of trends and patient characteristics

DARWIN EU® - Antipsychotic prescribing in the general population in Europe: a descriptive analysis of trends and patient characteristics

DARWIN EU® - DUS Characterising STOPP criteria medication use in people with recurrent falls

DARWIN EU® - Incidence of myoclonus in heart failure: a descriptive analysis in patients treated with sacubitril/valsartan and other treatments

DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics

DARWIN EU® -Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products

DARWIN EU® - Characterising the use of JAK inhibitors in Europe: a Drug Utilisation Study

DARWIN EU® – Incidence rates of venous thromboembolic events in patients with selected cancers

DARWIN EU® - Impact of risk minimisation measures related to the risk of meningioma in women using nomegestrol and chlormadinone

DARWIN EU® – Monitoring prescription of medicines for public health emergencies at risk of shortages

Meningioma medroxyprogesterone feasibility assessment in the IDA Germany and IMRD UK databases

DARWIN EU® - Clozapine and the incidence of agranulocytosis over time

DARWIN EU® - Eye disorders in women with breast cancer treated with anastrozole, letrozole or tamoxifen

DARWIN EU® - Drug utilisation study on antibiotics in the 'Access' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use

DARWIN EU® - Drug Utilisation Study on Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use

DARWIN EU® - Drug utilisation study in individuals with cystic fibrosis in Europe

DARWIN EU® - Characterisation of individuals with cystic fibrosis in Europe

Drug utilisation and patient characterisation of statin usage

DARWIN EU® - Drug Utilisation Study of terbinafine-containing products

DARWIN EU® - Time to onset of thromboembolic events in adults with selected types of cancer

DARWIN EU® - Assessment of immunoglobulin use in clinical practice

DARWIN EU® - Alzheimer's Disease: Incidence, Prevalence, and Individuals' Characteristics

DARWIN EU® - Treatment characterisation and post-diagnosis outcomes in Alzheimer's disease

DARWIN EU® - Determinants for use of GLP1 receptor agonists - a drug utilisation study

COPD, Bronchiectasis and Asthma Longitudinal Trends

Data elements collected

The data source contains the following information

Disease information

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

Pregnancy and/or neonates

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

No

Hospital admission and/or discharge

No

ICU admission

Is information on intensive care unit admission available?

No

Cause of death

Captured

Cause of death vocabulary

SNOMED CT

Prescriptions of medicines

Captured

Prescriptions vocabulary

other

RxNorm

Prescriptions vocabulary, other

OMOP (CVX)

Dispensing of medicines

Captured

Dispensing vocabulary

other

RxNorm

Dispensing vocabulary, other

OMOP (CVX)

Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

Indication vocabulary

Other

Indication vocabulary, other

Indication is not directly captured

Medical devices

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

Administration of vaccines

Yes

Procedures

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

Procedures vocabulary

SNOMED CT

Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?

The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

Biomarker data vocabulary

Other

Biomarker vocabulary, other

LOINC

Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

Diagnostic codes

Captured

Diagnosis / medical event vocabulary

SNOMED CT

Medicinal product information

Captured

Medicinal product information collected

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

Medicinal product vocabulary

Other

RxNorm

If 'other,' what vocabulary is used?

OMOP (CVX)

Quality of life measurements

Captured

Quality of life measurements vocabulary

Not coded (Free text)

other

Lifestyle factors

Captured

Lifestyle factors

Tobacco use

Sociodemographic information

Captured

Sociodemographic information collected

Gender

Pharmaceutical copayment

Quantitative descriptors

Population Qualitative Data

Population age groups

Paediatric Population (< 18 years)

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (\geq 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

General population; ~3300 physicians including office based GPs and specialists: cardiologists gastroenterologists pulmonologists rheumatologists diabetologists pediatricians neurologists psychiatrists gynecologists dermatologists ENT orthopedics urologists

~2700 practices

> 300M prescription orders, all specialties together (total DB)

Active population: ~18% national population (15M active patients 3 MAT)

Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

Population

Population size

43169181

Active population size

9254528

Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	5800455	1146728
Infants and toddlers (28 days - 23 months)	692605	90094
Children (2 to < 12 years)	3102732	679763
Adolescents (12 to < 18 years)	2005118	376871
Adults (18 to < 46 years)	14870203	2623576
Adults (46 to < 65 years)	11654330	2636480
Elderly (\geq 65 years)	10844193	2847744
Adults (65 to < 75 years)	5112724	1362049
Adults (75 to < 85 years)	4142454	979977
Adults (85 years and over)	1589015	505718

Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

0.33

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

3.56

Data flows and management

Access and validation

Governance details

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

Biospecimen access

Are biospecimens available in the data source (e.g., tissue samples)?

No

Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

Description of data collection

Anonymized patient records collected from patient management software used by GPs and selected specialists to document patients' clinical records

Event triggering registration

Event triggering registration of a person in the data source

Practice registration

Event triggering de-registration of a person in the data source

Other

Event triggering de-registration of a person in the data source, other

Lost to follow-up

Event triggering creation of a record in the data source

Physician encounter

Data source linkage

Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

Data management specifications that apply for the data source

Data source refresh

Quarterly

Informed consent for use of data for research

Not Required

Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

Data source preservation

Are records preserved in the data source indefinitely?

Yes

Approval for publication

Is an approval needed for publishing the results of a study using the data source?

No

Data source last refresh

15/12/2024

Common Data Model (CDM) mapping

CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

CDM Mappings

CDM name

OMOP

CDM website

<https://www.ohdsi.org/Data-standardization/>

Data source ETL CDM version

5.3.1

Data source ETL frequency

3,00 months

Data source ETL status

Completed